- Home
- BYRN vs VNDA Comparison
BYRN vs VNDA Comparison
Compare BYRN & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BYRN | VNDA |
|---|---|---|
| Founded | 2005 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 416.1M | 398.9M |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | BYRN | VNDA |
|---|---|---|
| Price | $16.85 | $7.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $41.50 | $14.00 |
| AVG Volume (30 Days) | 349.8K | ★ 1.3M |
| Earning Date | 02-06-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 543.53 | N/A |
| EPS | ★ 0.66 | N/A |
| Revenue | $110,853,000.00 | ★ $212,074,000.00 |
| Revenue This Year | $40.07 | $12.01 |
| Revenue Next Year | $20.31 | $21.57 |
| P/E Ratio | $25.41 | ★ N/A |
| Revenue Growth | ★ 50.99 | 11.12 |
| 52 Week Low | $13.68 | $3.81 |
| 52 Week High | $34.78 | $7.25 |
Technical Indicators
Market Signals| Indicator | BYRN | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 35.96 | 67.61 |
| Support Level | $17.05 | $6.75 |
| Resistance Level | $17.97 | $7.20 |
| Average True Range (ATR) | 0.82 | 0.47 |
| MACD | -0.07 | 0.04 |
| Stochastic Oscillator | 2.59 | 87.77 |
Price Performance
Historical ComparisonAbout BYRN Byrna Technologies Inc.
Byrna Technologies Inc is a designer, manufacturer, retailer, and distributor of technological solutions for security situations that do not require the use of lethal force. The company generates its revenue from the United States, South Africa, Europe, South America, Asia, and Canada.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.